Words similar to egfr
Example sentences for: egfr
How can you use “egfr” in a sentence? Here are some example sentences to help you improve your vocabulary:
It is also possible that EGFR amplification itself plays a role in acquired resistance, since imatinib-resistant clones have been shown to lack resistance mutations but contain amplified copies of BCR-ABL [11,28].
IGFR, [ 29 ] ], and one study used several cell lines and demonstrated distinct effects of the cell genetic background [ 25 ] . Down-regulated genes include bFGF, FGF-2, Topoisomerase II-α, EGFR,, human HDAC1, as well as cell cycle regulatory genes among others [ 30 31 32 33 34 35 36 37 ] . Regions in the bFGF promoter have been identified as associated with density-dependent down-regulation of bFGF [ 31 ] . The IGF-II P3 promoter is down-regulated as a function of cell density, and a 7-base pair sequence has been identified that plays a critical role in this down-regulation [ 32 ] . Neither the MoMuLV LTR or the htk promoters encode this sequence, although both encode a 10-base pair sequence that is identical to the P3 sequence with an insertion of 3 base pairs at position -1081.
Primers for EGFR analyses (exons 18–21) were as published [3].
A specific exon 20 mutation (T790M) was also detected by length analysis of fluorescently labeled (FAM) PCR products on a capillary electrophoresis device (ABI 3100 Avant, Applied Biosystems, Foster City, California, United States), based on a new NlaIII restriction site created by the T790M mutation (2369 C→T), using the following primers: EGFR Ex20F, 5′-FAM- CTCCCTCCAGGAAGCCTACGTGAT-3′ and EGFR Ex20R 5′- TTTGCGATCTGCACACACCA-3′.
We identified 60 lung adenocarcinomas from individual patients with tumors shown to be sensitive or refractory to single-agent gefitinib or erlotinib and evaluated these tumors for mutations in EGFR and KRAS . Collectively, nine of 38 (24%) tumors refractory to either kinase inhibitor had KRAS mutations, while zero of 21 (0%) drug-sensitive tumors had such mutations ( p = 0.02) (Table 1).
Loading...